RxDoctor Payments Data

Mukaramullah Syed, MD

Interventional Cardiology · McHenry, ILNPI 1538175583

Payments from drug & device makers

$1,554in general payments, 2019–2025

Across 72 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$291
  • Johnson & Johnson$206
  • Novartis$206
  • E.r. Squibb & Sons, L.L.C.$163
  • Kestra Medical Technology Services, Inc.$122
  • Pfizer$112
  • plus $453 from 9 others

What the payments were for

  • Food & beverage$1,52598%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,554 in reported general payments places this provider in the 15th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$263,016
Medicare patients
450
Services billed
2,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$145,379
EntrestoSacubitril/Valsartan71$94,542
BrilintaTicagrelor46$35,918
XareltoRivaroxaban25$28,580
MultaqDronedarone Hcl13$27,366
Repatha SureclickEvolocumab26$19,947
JardianceEmpagliflozin21$14,890
Ranolazine ErRanolazine77$12,468
MyrbetriqMirabegron11$5,553
Atorvastatin Calcium290$2,752
Metoprolol Succinate172$2,242
Potassium Chloride58$2,148
Nitroglycerin PatchNitroglycerin30$2,055
ClopidogrelClopidogrel Bisulfate148$1,630
Nebivolol Hcl32$1,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$145,379114 claims
NovartisEntresto$206$94,54271 claims
AstraZenecaBrilinta$77$35,91846 claims
Johnson & JohnsonXarelto$206$28,58025 claims
Sanofi-aventis U.S. LLCMultaq$93$27,36613 claims
Boehringer IngelheimJardiance$89$14,89021 claims
Astellas Pharma US IncMyrbetriq$21$5,55311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in McHenry

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →